key: cord-0788873-y81g5iqi authors: Saud, Zack; Tyrrell, Victoria J.; Zaragkoulias, Andreas; Protty, Majd B.; Statkute, Evelina; Rubina, Anzelika; Bentley, Kirsten; White, Daniel A.; Rodrigues, Patricia Dos Santos; Murphy, Robert C.; Köfeler, Harald; Griffiths, William J.; Alvarez-Jarreta, Jorge; Brown, Richard William; Newcombe, Robert G.; Heyman, James; Pritchard, Manon; Mcleod, Robert WJ.; Arya, Arvind; Lynch, Ceri-Ann; Owens, David; Jenkins, P Vince; Buurma, Niklaas J.; O’Donnell, Valerie B.; Thomas, David W.; Stanton, Richard J. title: The SARS-CoV2 envelope differs from host cells, exposes pro-coagulant lipids, and is disrupted in vivo by oral rinses date: 2022-04-15 journal: J Lipid Res DOI: 10.1016/j.jlr.2022.100208 sha: 3f30d6cd7c8300d3baa6ab1cb970ac139e62fcd7 doc_id: 788873 cord_uid: y81g5iqi The lipid envelope of SARS-CoV-2 is an essential component of the virus; however, its molecular composition is undetermined. Addressing this knowledge gap could support the design of anti-viral agents, as well as further our understanding of viral-host protein interactions, infectivity, pathogenicity, and innate immune system clearance. Using lipidomics analyses, we revealed that the virus envelope comprised mainly phospholipids (PL), with little cholesterol or sphingolipids, indicating significant differences from the composition of host membranes. Unlike cellular membranes, procoagulant aminophospholipids were present on the external side of the viral envelope at levels exceeding those on activated platelets. As a result, virions directly promoted blood coagulation. To investigate whether these differences could enable selective targeting of the viral envelope in vivo, we tested whether oral rinses containing lipid-disrupting chemicals could reduce viral infectivity. Products containing PL-disrupting surfactants (such as cetylpyridinium chloride (CPC)) met European virucidal standards in vitro; however, components that altered the critical micelle concentration reduced efficacy, and products containing essential oils, PVP-I, or Chlorhexidine were ineffective. This result was recapitulated in vivo, where a 30-second oral rinse with CPC mouthwash eliminated live virus in the oral cavity of COVID-19 patients for at least one hour, while PVP-Iodine and saline mouthwashes were found ineffective. We conclude the SARS-CoV-2 lipid envelope (i) is distinct from the host plasma membrane, which may enable design of selective anti-viral approaches; (ii) contains exposed PE and PS, which may influence thrombosis, pathogenicity, and inflammation; and (iii) can be selectively targeted in vivo by specific oral rinses. The lipid envelope is critical to the structure and function of SARS-CoV2, as for all enveloped viruses, such as influenza, HIV, herpes simplex virus, MERS and SARS-CoV (1, 2) . Yet despite this, the potential of the envelope as an antiviral target has not been exploited, beyond being the target of handwashing and gels, where soap or high concentrations of ethanol (>60%) dissolve the lipids and inactivate the virus. This is in part because, unlike our extensive knowledge of the structure and function of the proteins in the virion (1, 2) , there is no information on the lipid composition of the SARS-CoV2 envelope -indeed, viral lipid envelopes overall are surprisingly unstudied, and their detailed lipid composition unknown. Coronaviruses bud from the endoplasmic reticulum/Golgi intermediate complex (ERGIC) and exit via lysosomal secretion (3) (4) (5) (6) (7) (8) , thus the composition of the virion envelope may differ significantly from plasma membrane, enabling selective therapeutic targeting that avoids damaging host membranes (9) . Furthermore, the envelope is not simply a structural component of the virion, with lipids themselves being potent bioactive molecules. Mammalian cells maintain aminophospholipids (aPL), such as phosphatidylethanolamine (PE) and phosphatidylserine (PS), in their inner plasma membrane leaflet using energy-dependent enzymes, however these control mechanisms are not present in the virus. This raises the possibility that the external face is enriched in PE and PS, which are highly prothrombotic, and furthermore could directly promote virion uptake via apoptotic cell mimicry (10) (11) (12) (13) (14) (15) (16) . Indeed, a recent study showed that PS is present on the surface of the virions and that PS receptors on host cells can support entry (17) . However, that study relied on an ELISA method and neither the amounts nor the molecular species of PS exposed were demonstrated, nor was the presence of PE shown. Phospholipids (PL) such as lysophospholipids and sphingolipids/ceramides are proinflammatory effectors (18, 19) , and can interact with complement to promote a pro-inflammatory environment (3, 11, 20) , while lysophospholipids signal through G-protein coupled receptors causing immune cell migration and apoptosis (21) (22) (23) (24) . Understanding virion lipid composition therefore has potential to inform our understanding of virus pathogenesis, dissemination, and how the virion promotes transition from early infection to severe inflammatory thrombotic COVID19. Following on from public health advice on handwashing, which disrupts the lipid envelope, we considered whether similar approaches using formulations that are non-toxic in vivo could represent potential anti-viral strategies directed at reducing SARS-CoV2 transmission, and published an evidence review on this topic in 2020 (25) . The lipid membranes of enveloped viruses, including some coronaviruses, had previously been shown to be sensitive to disruption by lipidomimetic agents and surfactants (25) . Thus, we hypothesised that the SARS-CoV2 virus might also be susceptible to J o u r n a l P r e -p r o o f inactivation by components in widely-available oral rinses, such as ethanol/essential oils, cetylpyridinium chloride (CPC) and povidone-iodine (PVP-I) (25) . If lipid-disrupting components in oral rinses can dissolve the virion envelope, this approach could in theory reduce the risk to healthcare workers or carers treating individuals asymptomatically (or symptomatically) carrying the virus. Early in the pandemic, mouthwashes were employed empirically in outbreaks in China but without evidence of efficacy (26). Since then, a series of studies have emerged indicating that some can inactivate SARS-CoV2 in vitro, including a systematic review (27) (28) (29) (30) (31) (32) . Furthermore, a recent small study suggested that oral rinsing could shorten hospital stay, while another suggested that oral and nasal rinsing could reduce both disease and symptoms in healthcare professionals (33, 34) . Recently, WHO included a recommendation that PVP-I could be used to reduce the risk of clinical transmission in dentistry (https://www.who.int/publications/i/item/who-2019-nCoV-oral-health-2020.1). However, despite all these encouraging studies, the relative efficacy and the persistence of mouthwashes in vivo is currently unknown. Importantly, in order to most effectively target the virus in the oropharynx, a detailed knowledge of the lipid composition is required, so that the most appropriate formulation is selected. To address these questions, we used lipidomics to provide the amount and molecular diversity of envelope lipids and the levels of external facing aPL in virus cultured from two different cell lines. Our data provides the first complete characterisation of a viral lipid envelope and shows a PL rich membrane that also contains several lysoPL, but is relatively low in cholesterol, sphingomyelin (SM) and other lipids. Sufficient aPL were present to enhance coagulation of plasma in vitro using live virus. Following this, in vitro studies tested the interaction of varying lipid-membrane disrupting mouthwash formulations and components. Importantly, only a subset of rinses demonstrated efficacy, specifically those containing surfactant-and polar components. Furthermore, a randomised controlled clinical study in COVID 19 patients showed the virucidal effect of a surfactant-containing rinse against SARS-CoV2 in hospitalised patients. These studies demonstrate the accessibility and importance of lipids as a potential target for anti-viral approaches, which is unlikely to be impacted by mutation of the virus. They also suggest that targeting virus lipids in the oropharynx may be an important component of risk management in healthcare during the COVID19 pandemic, and in the context of other enveloped respiratory viruses including coronaviruses and seasonal influenza viruses in the future. Aqueous solutions CPC was dissolved in deionised water at 0.07% or 0.1% (w/v). For aqueous solutions containing LAE, a 33 mM stock solution was prepared by dissolving 693.2 mg of N-ethyl lauroyl arginate hydrochloride (Fluorochem, used as received) in deionised water (Elga Purelab Flex), adjusting the pH to 7 using a NaOH solution (pH was determined using a Hanna Instruments pH210 microprocessor pH meter with a VWR simple junction universal combined pH/reference electrode) and making up the solution to 50 mL. The required LAE solutions were then prepared by mixing 1 mL of the stock solution and 9 mL of deionised water (3.3 mM), 3 mL of the stock solution and 7 mL of deionised water (9.9 mM) and 1 mL of the stock solution, 6.7 mL of deionised water and 2. Flex). The pH was adjusted to 6 using a NaOH solution (pH was determined using a Hanna Instruments pH210 microprocessor pH meter with a VWR simple junction universal combined pH/reference electrode) followed by making up the solution to 1 litre. The solutions of CPC in combination with citrate and benzoate was prepared by dissolving ~0.11 g of CPC with 0.12 g of citric acid and/or 0.07 g of benzoic acid in deionised water, adjusting the pH as before, and making up to 100 mL. The solution containing deionised water, ethanol and thymol was prepared by dissolving 0.1675 g of thymol in 50 mL of ethanol; 2.3 mL of this solution was combined with 7.7 ml deionised water. All commercial mouthwash preparations are listed in Table 2 . Cells and viruses Virucidal assays utilised VeroE6 or A549 cells, a gift from the University of Glasgow/MRC Centre for Virology, UK. To enhance infectivity and produce a more sensitive cell line for detection of virus, both cell types were transduced with lentiviruses encoding ACE2 and TMPRSS2, then drug selected as described (35) . The England2 strain of SARS-CoV2 was provided by Public Health England, and amplified in VeroE6 cells before being harvested from the supernatant. All cells were grown in DMEM containing 2 % (v/v) FCS, and incubated at 37 °C in 5 % CO2. Virucidal assays Virucidal activity of mouthwash was studied in media containing 100 μL mucin type I-S, 25 μL BSA Fraction V, and 35 μL yeast extract to mimic oral secretions. 100 μL of this mixture was added to 100 μL of virus suspension, and 800 μL of the test-product or medium as control. After 30 seconds, virucidal activity was neutralised by 10-fold serial dilution in ice-cold DMEM (containing 10% FCS). Alternatively, virus was purified by size-exclusion chromatography (SEC) to prevent direct cytotoxic effects of the products on the cell monolayer; 100 μL of the mixture was added to a microspin S-400 HR column, and centrifuged for 2min at 700 x g. A 10-fold serial dilution was then made of the flow-through in DMEM containing 10% FCS. Virus was titrated by plaque assay; serial dilutions were used to infect VeroE6/ACE2/TMPRSS2 cells for 1 h. Following this, cells were overlaid J o u r n a l P r e -p r o o f with DMEM containing 2 % FCS, and 1.2 % Avicel®. After 72 h, the overlay was removed, and the monolayer washed and fixed with 100% methanol. Monolayers were stained with a solution of 25% (v/v) methanol and 0.5 % (w/v) Crystal Violet, then washed with water, and plaques were enumerated. For measurement of toxicity, monolayers were similarly incubated, stained with crystal violet, and scored by eye for live cells. criteria for peaks were those at least 5:1 signal-to-noise ratio, and with at least 7 points across the peak. All targeted lipidomics data were statistically analysed using Students T-test, followed by Benjamini Hochberg correction where any lipid category had >20 variables. All statistical data is provided in Source Data file. adducts. Next, all matches with deltaPPM >10 were manually removed. Matches to GL in negative ion data, and matches to FA in positive ion data were removed and reassigned as unknowns, with LMSD identifiers removed. In LipidFinder, to remove baseline noise from blanks, the mean of the blank signals for each ion is subtracted from each lipid sample, where they match by RT and m/z value. Then, every frame that is less than 3 times greater than the solvent mean for every sample is removed. After processing, a manual step was also included where ions that were represented in blank samples at J o u r n a l P r e -p r o o f >15% the virus sample were judged to be background and removed. Retention time windows based on standards were estimated as follows: lysoPE/PC 10-11 min, PE/PC 6-7 min, Lyso PI 10-12 min, PG 2-4 min, PI 8-10 min, LPG 4.5-5.5 min, MAG/TAG/DG 1-3 min, SM 9-11 min, Cer 1.5-3 min. Note that many ions listed in unknowns are likely to be in source fragments, that will match LMSD entries, that were moved to unknown since they are outside the expected RT window. Mass accuracy is broadly considered down to 3 decimal places. Note that this is a largely unvalidated dataset and provided for further information mining purposes. Data is in SupplementaryData2.xls Table 5 . For the targeted assay, we first generated quantitative data (ng/sample) for all lipids measured in all virus extracts. However, obtaining accurate virus particle numbers, so that data can be converted to ng/particle number, proved difficult. Standard measures of PFU are not useful since they do not correlate with particle numbers. We attempted to use nanoparticle tracking analysis, however the accuracy of particle counts was insufficient for our needs, potentially due to aggregation of virus particles following categories and within the categories themselves, without the need for accurate particle counts. of conducting assays with live SARS-CoV2 virus, we used a classical assay that doesn't require specialist equipment (39) . Here, the activity of both intrinsic and extrinsic pathways of coagulation are measured in re-calcified plasma activated on contact with a negatively-charged surface provided by a glass test tube, and the ability of live virus to modulate coagulation was tested. Purified SARS-CoV2 virus was resuspended in PBS, then 50 µl added to 50 µl of normal pooled human plasma (Alpha Laboratories, CCN-10), in a glass tube. As a negative control, 50 µl of PBS was added to plasma instead of virus. Samples were incubated at 37 C for 1 minute, then 50 µl pre-warmed 20 mM CaCl2 added. Samples were incubated at 37 C and the time until a visible clot formed was measured by visual inspection using a stopwatch. Clot time is defined as any visual evidence for formation of a gel-like structure, recognising that these can either be strong and stable, or looser. In control samples, the fibrin clot was formed in around 2 min (120 sec). and actin (cells). Virions were resuspended in NuPAGE LDS sample buffer (Thermo) containing 10 % dithiothreitol (DTT), then samples were loaded onto 14 % Tris-Glycine pre-cast gels (Biorad), and run for 1 h at 20 V. Protein was transferred to nitrocellulose membranes by semi-dry transfer, blocked in blocking buffer (5 % non-fat milk in PBST) for 1 h, then stained with primary antibody for 1 h at room temperature. Membranes were washed, incubated with secondary antibody for 1 h at room temperature, washed, developed with Supersignal West Pico (Thermo), and imaged using a G:Box Chemi XX6 (Syngene). Antibodies were all diluted in blocking buffer, and were rabbit anti-actin (A2066, Sigma-aldrich 1:2,000) and mouse anti-SARS-CoV2 Spike (Clone 1A9, Insight; 1:2,000), as well as antimouse HRP or anti-rabbit HRP (GE Healthcare; 1:2,000). Statistical analysis for clinical study: At termination of the study, blinded data was analysed by an independent observer (RGN) who was not involved in the design of the clinical trial or randomisation. All original data on viral load (PFU/mL of saliva), together with the Log2 fold change in from baseline to 60 minutes post-treatment is presented. The viral load from baseline to 60 minutes post-treatment was used to calculate a geometric mean ratio (mean change from baseline to post-treatment). Data was then log transformed. Where virus was not detected, zero values were replaced with 4, just below the lower limit of detection for the assay (5 PFU/ml). Lower and upper confidence limits from the relevant mean and SD on the transformed scale and t and p-values were determined using unpaired t test (Table 5 ). SARS-CoV2 England 2 strain was grown in VeroE6 or A549 monolayers and purified using density gradient centrifugation. A549 stably expressed ACE2 and TMPRSS2 to enhance infectivity (35) . Purity of virus was confirmed by Nanoparticle tracking analysis, with a single peak observed at approximately 100nm (Figure 1 A) , and by western blot demonstrating absence of actin as a cellular marker from the purified virus (Figure 1 B, Supplementary Figure 1 A,B) . The absence of serum lipid contamination in purified virus was confirmed using precursor scanning for PE, PC and CE (data not shown). Figure 1C ). Some significant differences in low abundance lipid categories such as Cer/DHCer, LPE, PS and TAGs were also seen (Figure 1 C insets) . The SARS-CoV2 membrane contains low amounts of cholesterol, SM and PS, relative to other PL. Next, mol% was calculated for PL and sphingolipids only, since this allows comparison with older studies on composition of intracellular membranes of mammalian cells, which used thin layer J o u r n a l P r e -p r o o f chromatography coupled with phosphate analysis to measure these lipid categories (Table 1) . Unfortunately, very few studies on cell membrane composition exist and these used older methods very different to LC/MS/MS, as well as very different cell types. Nonetheless, it is useful to compare these with SARS-CoV2, as shown in Table 1 (see Discussion) . For both virus preparations, the molar ratio of cholesterol:PL was similar, at 0.0005 or 0.00061 mol:mol, A549 or Vero, respectively. This indicates that the membrane is virtually devoid of cholesterol, in combination with a high PL content. Additionally, the mol% of SM and PS are relatively low (Table 1) . Overall, the data characterises SARS-CoV2 as a membrane highly enriched in PL, primarily PE, PC and PI. Next the individual molecular species within categories were compared. Within each cell type, the levels of specific lipids were very similar, indicating that the viral lipidome is relatively stable ( Figure 2 , 3A). However, significant differences were seen between Vero versus A549-derived virus across This profile was maintained strongly across all PL classes, as well as lysoPLs. Generation of an untargeted lipidomics dataset for future lipid mining. Next, to generate an untargeted dataset, virus lipids from Vero cultures were separated using hydrophilic interaction liquid chromatography (HILIC) in triplicate, subtracting extracted blanks, scanning from 50-2000 amu, at 20K resolution. Retention time windows were identified using internal standards for PC, PE, PG, PI, lysoPC, lysoPE, lysoPG, lysoPI, glycerides, SM and Cer. Since electrospray ionisation high resolution mass spectroscopy (ESI-HRMS) runs contain large numbers of artefactual ions including in source fragments, isotope peaks, common contaminant ions in blanks, salt clusters, ion stacks and other features, two informatics approaches were applied to clean up the dataset. First, XCMS was used to align and integrate peaks, before a full clean up using LipidFinder 2.0 was performed (36, 37) . LipidFinder is designed to remove as many of these artefacts as possible while retaining real lipids, and also subtracts blank signals to correct for background. Large numbers of ions were returned in the dataset and putative matches are provided from the LIPID MAPS Structure Database (LMSD) Bulk search, mapped to the LIPID MAPS classification (41,42) (Supplementary Data2.xls). Using internal standards, we isolated ions matched to specific categories as described above, and putative matches that fell outside retention time windows were moved to the Unknown category, and names J o u r n a l P r e -p r o o f removed. Since this analysis is based on precursor mass only, bulk annotation should be used, and putative matches are provided as unvalidated examples of potential structure, where shorthand annotation is not available (e.g. prenols, polyketides, saccharolipids) (42) . We recommend if this data is to be used that investigators rigorously confirm structures of interest using MS/MS and we would be able to provide lipid extracts on request in order to help such an endeavour. Overall, our lipidomics data establish SARS-CoV2 membrane as highly enriched in PL, particularly PC, PE and PI, but with rather low levels of cholesterol, PS and SM. They also show that the membrane is influenced to some extent by the host cell of origin in relation to specific molecular species of lipids detected. Mammalian membranes maintain asymmetry via the action of flippases and floppases which retain aPL on the inner membrane (43) . Here, we determined the proportion of PE and PS molecular species on the surface of viral particles using derivatisation-LC/MS/MS (38) . Adding together the molecular species measured, the external levels of aPL were 48% or 52% for virus from A549 or Vero cells respectively. However, for Vero cells, the % of PS externalised was consistently lower, around 27%, versus 56% for A549, with the level of PS 18:1_18:1 being significantly reduced (Figure 4 A) . For PE, the overall external levels were 52% for both cell types. Generally, the pattern of external aPL was similar for both virus preparations, with around half of the aPL being exposed on the external leaflet ( Figure 4A ). Thus, unlike mammalian cells, SARS-CoV2 particles are unable to maintain asymmetry of aPL. As a comparison, we previously showed that when platelets are thrombin activated, calciumdependent scramblase externalises PE/PS, to only around 3-4 mol%, from around 0.2-0.5% basally (43) . This is sufficient to support complete binding and activation of coagulation factors, leading to haemostasis and thrombosis (43) . Thus, considering the total virus levels of PE and PS (Figure 1 C) , with the proportions detected externally (Figure 4 A), these particles will expose some external facing PS, along with very high levels of external PE, far higher than would be present on platelets during physiological or pathological haemostasis. Given the key role of external facing PE and PS in together supporting blood clotting, we next tested whether virus could regulate the ability of plasma to coagulate in vitro. Gradient purified virions were added to plasma in the presence of CaCl2 and the Activated Partial Thromboplastin Time (APTT) was measured as outlined in Methods. Here, the presence of a glass surface stimulates the "contact" or J o u r n a l P r e -p r o o f intrinsic pathway, resulting in a cascade of factor activation and eventually fibrin clot formation. Virions dramatically reduced the time taken for clot formation in a concentration dependent manner, at minimum concentrations of ~6x10 5 PFU/ml (Figure 4 B) . Although data is not available on blood virus levels in severe disease, we note that the levels able to enhance clot formation are well within the range of levels detected in saliva, BAL and subglottic aspirates in patients, who frequently carry loads of 10 6 -10 7 , and can even be above 10 8 PFU/ml (44) . Having characterised the envelope composition, we next investigated whether it was possible to disrupt the lipid envelope using oral rinses that have been designed to be antimicrobial, but also contained constituents potentially capable of targeting generic PL based membranes. To define biological activity, we assessed viral infectivity in vitro, in the presence of a soil load to mimic the components of the nasal/oral cavity. To examine the activity of a range of products, seven formulations were tested ( Table 2) An important refinement was the use of VeroE6 which stably overexpress ACE2 and TMPRSS2. This significantly improves viral infectivity, with SARS-COV2 entering >1log10 more efficiently than parental VeroE6, significantly enhancing assay sensitivity (35) . Rather than BSA alone, our soil load comprised mucin (type I-S), BSA and yeast extract (as in (29) underwent SEC, the flow-through was non-toxic against the cell monolayer for all products with the exception of SCD Ultra (Figure 4 C) . SEC was therefore used for all in vitro mouthwash testing. These optimisations enabled the detection of a >5-log10 decrease in virus titre, with the exception of SCD Ultra for which a >4-log10 decrease was measurable. This is above the 4-log10 reduction in activity specified by EN14476, allowing the testing of mouthwash to international virucidal standards, as detailed below. Next, the ability of mouthwash to reduce virus infectivity, after a 30-second exposure in a soil load, was tested using the optimised plaque assay. Two CPC-containing mouthwashes (Dentyl Dual Action, Dentyl Fresh Protect) and a mouthwash containing 23% v/v ethanol/LAE (Listerine® Advanced DGT) eradicated the virus completely, giving >5-log10 reduction in viral titres, and thus met EN14476 as a virucide. In contrast, only moderate effects (~3-log10 fold reduction) were observed with PVP-I (Videne), CPC/sodium citric acid/benzoate (SCD Ultra) and 21 % v/v alcohol/essential oils (Listerine® Cool Mint) (Figure 4 E) , which failed to meet EN14476. Chlorhexidine (Corsodyl; <2 log10 fold reduction) was least effective. For products with antiviral activity, it is relevant to determine selectivity for the virus as opposed to host cells, since potential toxicity in vivo should be considered. We showed that the SARS-CoV2 membrane is similar to ER/Golgi in terms of PL composition (Table 1) , and unlike plasma membrane is extremely low in cholesterol and SM. However, whether this is sufficient to reveal differential impacts of oral rinses needed to be experimentally determined. We compared the sensitivity of VeroE6 cells Despite all mouthwashes containing antibacterial compounds, they demonstrated widely varying abilities to inactivate SARS-CoV2, indicating that careful selection for clinical use may be important. To determine which components were responsible for this activity, SARS-CoV2 was exposed to active constituents (alone or combined) from the relevant rinses, using concentrations found in individual formulations (Figure 5 B, Table 2 ). CPC, the active component in Dentyl Fresh Protect, eradicated live virus at both concentrations tested (Figure 5 B) . Dentyl Dual Action contains CPC/isopropyl myristate (IPM) in a biphasic aqueous-oil system that requires shaking before use. CPC is predominantly in the aqueous phase, while IPM is predominantly in the oil layer. The fully-shaken rinse completely eradicated live virus (Figure 5 B) . The aqueous CPC layer (without prior mixing) was also effective, as was the aqueous layer obtained after shaking followed by 2 min settling (to ensure IPM saturation of the CPC layer) (Figure 5 B) . Thus, CPC alone can eradicate SARS-CoV2 and IPM isn't required. One mouthwash (SCD Ultra) showed only a 3-log reduction in virus titres despite containing CPC (Figure 4 E). This formulation also contains citrate and benzoate. When these were separately added to CPC, citrate had no effect, however benzoate reduced the ability of CPC to kill virus (Figure 5 C). Therefore, while surfactants such as CPC are essential for antiviral activity, additional mouthwash components may reduce this effectiveness in inactivating SARS-CoV2. (48) . As our patients were ill enough to be admitted to hospital, many were likely beyond this timepoint. Unfortunately, this was not known at the time sample collection was initiated and only became evident towards the end, with the study terminated at 6 months. By then, new UK daily cases had decreased from 55 (Table 1 ). Coronaviruses have long been known to be generated on the ERGIC membrane (3-8), however, how this related to their lipid composition was so far unknown. Here, we found that the SARS-CoV2 membrane is primarily comprised of PC, PE and PI, while having low levels of free cholesterol, PS and SM. This appears most similar to ER, although with even lower proportion of PS, SM and cholesterol than previously reported for that membrane compartment, using older methods. In the mammalian plasma membrane, cholesterol is often concentrated in specialised regions which support receptor dependent signalling, called lipid rafts (50) . Our data suggest these will be absent from the viral envelope. Furthermore, the cholesterol in plasma membranes regulates fluidity and reduces permeability to small molecules, while SM is also important for reducing fluidity (51) (52) (53) . Thus, the viral envelope and plasma membrane will be very different biophysically. Similarly, bacterial membranes are also considered to be devoid of cholesterol. In this context, this is exploited therapeutically since cholesterol protects host cells from disruption by antimicrobial peptides which directly insert in the bacterial membrane (54) . Having described the virion envelope in detail, it is now possible to test targeted strategies using liposomes that mimic the SARS-CoV2 membrane, for example by generating liposomes with the exact lipid molecular composition. Furthermore, we demonstrate that the virion membrane contains lysoPL, from PG, PE and PC, noting that these are known bioactive lipid signalling mediators, and their presence in the envelope could impact on host inflammatory responses to infection. It was recently reported that coronaviruses exit via lysosomal secretion instead of the biosynthetic secretory pathway (55) . Lysosomes contain high levels of SM and cholesterol (Table 1) , thus the lack of these lipids indicates that lysosomal passage of virus doesn't appear to impact envelope composition. Examining the different lipid categories at the molecular species level, a high proportion of saturated/monounsaturated FAs were noted, with little J o u r n a l P r e -p r o o f PUFA evident. This most likely reflects the typical FA composition of cultured cells which tend to be lower in PUFA than primary tissues. In human disease, the SARS-CoV2 virus will be actively replicating in oral, nasal and airway epithelia. Studies on airway and tracheal cells have shown their FA composition to be similar to what was seen here, but with significantly more 18:2 and 20:4, which becomes lowered during cell culture (56, 57) . Thus, virus generated in human airways in vivo may have more PUFA than found herein, but this remains to be determined. Notably, we found significant differences in SARS-CoV2 virus lipids, depending on the host cell in which they were generated. This may relate to subtle differences in host cell ER membranes between the cell types. Importantly, inflammation has a significant impact on host cell lipid metabolism, and how this influences virion envelope composition now needs to be tested. Furthermore, whether lipid composition is different in other strains of SARS-CoV2 is also unknown. This question is being currently addressed for multiple variants of concern (VOC) in our laboratory. Here, we showed that SARS-CoV2 exposes around 50% of its total molecular species of aPL on the surface of the particle ( Figure 4B ). As a caveat of the method, membrane proteins or sugars could in theory hinder derivatisation of aPL, and so this value may be a lower-level estimate. In primary cells, energy-dependent processes maintain asymmetry of plasma membranes. This ensures that very low mol% of PE and PS are exposed on the surface, for example, only 3 -4 % is present on platelets following thrombin activation (43) . This is because PE and PS promote coagulation, complement binding and uptake of apoptotic cells through their electronegative interactions with Ca 2+ ions and various proteins (3, 20, 43) . Although the overall amounts of PS appear to be rather low in virions, PE levels are similar to plasma membrane (Table 1) . Thus, exposure of 50 % of aPL on the surface will result in levels of external PE that are around 12-fold-higher than activated platelets (43) . In line with this, we found that purified virions significantly accelerate plasma coagulation in vitro (Figure 4 B) , although we stress that in vivo there will be many sources of membrane in inflamed tissue in COVID which may contribute to thrombosis. In addition, a recent study showed (using a less specific ELISA) that levels of PS on the surface of SARS-CoV2 are sufficient to support PS-receptor dependent viral entry (17) . Our work extends this significantly by reporting on the ng amounts of PS and PE present, the proportions of PE and PS that are externalised, and the specific molecular species of PE and PS in the membrane. In addition to SARS-CoV2, PS has been implicated in the cellular uptake of several other viruses, thus knowing how much and which molecular species are external facing on the envelope is relevant to other infectious diseases (10) (11) (12) (13) (14) (15) (16) . In summary, our study and others suggest that targeting aPL could support anti-thrombotic, anti-inflammatory or anti-viral strategies for COVID19. Our findings could also be relevant for other enveloped respiratory viruses such as influenza which has long been considered to trigger thrombotic complications of atherosclerosis, including myocardial infarction. Winter peaks in influenza are often followed two weeks later by a peak in ischemic heart disease, hypertension and cerebrovascular disease deaths. Furthermore, many acute vascular events follow upper respiratory infections (reviewed in detail in (58)). A recent study found that emergency department visits for respiratory illness were both associated with, and predictive of, cardiovascular disease mortality in adults >65 yrs (59) . Furthermore, in a meta-analysis, influenza vaccination was associated with lower risk of adverse cardiovascular events (60) . The mechanisms are unknown and a vascular inflammatory component is very likely to play a role. Thus, other enveloped viruses are also strongly associated with thrombotic events, however whether virions themselves directly contribute to coagulation has never been evaluated. Future studies are now needed to investigate whether the virus membranes and/or particles in the circulation could contribute to coagulation, and which membranes support coagulation during infection, including blood cells and inflamed tissue. SARS-CoV-2 RNAemia has been reported in severe cases (61) , and whilst it is unclear whether this represents virus particles, both viral genome and proteins have been detected broadly distributed throughout the body; indicating at least some systemic transfer in severe disease (62) (63) (64) . These studies will also need to delineate the molecular mechanisms involved, including the participation of PS/PE. Nevertheless, knowing the levels and proportion of PE and PS on the outside of the virion envelope is a novel finding that will help further our understanding of the biology of the virus, and could be applicable to other respiratory enveloped viruses, such as influenza. Having determined the composition of the lipid membrane, we next tested the impact of common mouthwash formulations, focusing on surfactants which we reasoned would effectively target a PLrich membrane. Our data significantly extends other recent studies on enveloped viruses. For example, dequalinium/benzalkonium chloride, PVP-I and ethanol/essential oils reduced SARS-CoV2 infectivity in vitro by up to 3-log10 (29), while infectivity of HCoV229E was reduced by 3-4-log10 using CPC, ethanol/essential oils and PVP-I (27, 30) . Also, a moderate (3-log10) antiviral effect of thymol/ethanol is consistent with an in vivo study on Listerine®Cool Mint against HSV (40,65). However up to now, only one of the products (Listerine®Antiseptic, 26.9% ethanol/essential oils) has achieved 4-log10 kill required to pass EN14476 as a virucidal, although this was tested against HCoV229E rather than SARS-CoV2 (30) . Here, we employed live SARS-CoV2 England2 strain, and demonstrated that several mouthwashes (Listerine®Advanced DGT, Dentyl Fresh Protect, Dentyl Dual Action) pass EN14476 against this virus. Importantly, efficacy was not dependent on 'classical' antibacterial components of mouthwashes, but instead was critically dependent on the presence of surfactant (CPC/LAE). Whether any of the lipid J o u r n a l P r e -p r o o f disrupting components would function in this way was not predictable from the outset; efficacy is determined by both molecular makeup and concentration, with some detergents (e.g. Tween20) not inactivating SARS-CoV2 even at 0.5 %, while others (e.g. Triton X-100) lyse it completely at 0.1 % (66). Thus, our finding that components such as essential oils do not eliminate infectivity, is equally important as the finding that CPC and LAE in mouthwashes do. CPC-containing mouthwashes were previously reported to reduce infectivity of other enveloped viruses, including HSV (67) and influenza (46) , while LAE has shown antiviral activity towards HSV-1, vaccinia virus and bovine parainfluenzae 3 (68) . Thus, our results may be generally applicable to all enveloped viruses. The finding that LAE is virucidal both above and below cmc, and with or without ethanol, suggests that the virucidal activity of LAE is independent of micellar self-aggregation, and that the transfer of individual surfactant molecules into the viral envelope destabilises the bilayer. The ability of CPC alone, at two concentrations above its cmc (1 mM), to fully inactivate SARS-CoV2 is likely due to micelle-forming surfactants having a very different "packing parameter" than the lipids in the viral bilayer (69). Mixing the surfactant with lipids may increase the local curvature, causing formation of separate micelles, effectively dissolving the bilayer. This is in line with reports showing evidence from electron microscopy that CPC disrupts the viral envelope (46, 47) . Finally, the effect of surfactant was not charge-dependent as both cationic and anionic surfactants were virucidal (Figure 5 B, Figure 7 ). Whilst surfactants are highly antiviral in isolation, other mouthwash components may reduce their effectiveness. Benzoate can bind with CPC, dramatically reducing its cmc, without changing its micellar morphology (70, 71) . Such interactions are typical for combinations of cationic surfactants and aromatic anions (72) . A reduced cmc indicates a lower concentration of non-aggregated surfactant. The reduction in virucidal effect of CPC caused by benzoate in SCD Max may therefore be due to it reducing the concentration of monomeric CPC. Taken together, our data indicate that whilst product selection is typically made on the basis of individual principal components e.g. CPC, chlorhexidine, or iodine, interactions between ingredients need to be carefully considered. To address the theoretical potential for toxicity of mouthwash with long term use, we compared cell disruption with viral infectivity and found some minor differences (Figure 4 F) . These could be due to the fact that the virus membrane is deficient in some lipids that are known to be enriched in host plasma membrane (e.g. cholesterol, SM). Notably however, >25 % of UK adults use mouthwashes daily with no ill effects reported, while mouthwash was used by almost 200 million Americans in 2020 (73) (https://www.statista.com/statistics/286902/usage-mouthwash-dental-rinse-us-trend/). While CPC-containing mouthwashes can show cytotoxicity against monolayers in vitro, the lack of observed toxicity in vivo likely reflects the complex, differentiated, multicellular nature of primary oral epithelia (74) . Furthermore, studies have demonstrated the effectiveness of CPC-containing mouthwashes in J o u r n a l P r e -p r o o f safely reducing gingival inflammation, despite concerns regarding perturbation of the oral microbiome (75, 76) . In patients with COVID19, increased disease severity was recently shown to be associated with moderate/severe periodontal disease (77) . Associations between periodontal inflammation, cytokine release, and altered lipid metabolism have also been established in a range of co-morbidities that associate with poorer COVID19 outcome, including neurodegeneration, diabetes and cardiovascular disease (78). Thus, as part of maintaining routine oral health, mouthwash use has potential to impact transmission and disease through both direct and indirect mechanisms. In many parts of the world, clinical investigations of the oropharynx, including in primary care, dentistry, ENT, and maxillofacial surgery, have been severely curtailed due to the risk of SARS-CoV2 transmission from pre-clinical asymptomatic patients. Here, interventions to reduce the salivary load in patients might be of benefit. Ideally, a large-scale trial would assess the ability of oral rinsing to impact on disease transmission and disease severity however this was not possible in the pandemic situation. Instead, we tested the in vivo efficacy of mouthwash on hospitalised 'moderate' COVID patients (not requiring intensive medical support or ventilation) and showed a strong impact of surfactant-containing oral rinses on live virus load in saliva. Only three other studies have attempted to address these effects in vivo during the pandemic and both were inconclusive due to small numbers of patients, and the use of qPCR rather than live virus titration to determine virus load (28, 79, 80) . Our clinical study was designed in the early part of the pandemic, prior to data becoming available showing that throat virus falls to undetectable levels by 9 days post symptom onset (48) . Thus, our study was challenged by recruitment (inability to provide informed consent and provide salivary samples), co-morbidity and the inability to predict patients with saliva containing live virus (<40% of patients). The study was concluded at 6 months with 78 patients randomised; the largest sample to date of any study, with 27 patients having live virus in their saliva. While all mouthwashes were generally beneficial at 1 minute, the CPC mouthwash (Dentyl Dual Action), was the most effective, significantly reducing live viral load over the entire time course, and completely eliminating it for 1h in multiple patients. An important caveat is that mouthwash use will not target virus in the lower respiratory tract. Whilst it remains unclear whether transmissable virus arises from the upper-or lower respiratory tract, we have shown that infectious virus is found more commonly in the upper than the lower respiratory tract (44) . Nevertheless, it remains the case that mouthwashes can destroy enveloped viruses in the oral cavity for sufficient time to enable a dental or oral investigation. Future trials will be required to ensure that this effect is consistent in larger cohorts. However critically, current WHO guidance proposes the use of hydrogen peroxide and PVP-I mouthwashes in dental surgery during the COVID19 pandemic (https://www.who.int/publications/i/item/who-2019-nCoVoral-health-2020.1). However hydrogen peroxide only weakly inactivates SARS-CoV2 (81), and our J o u r n a l P r e -p r o o f data shows that surfactant-containing mouthwash is more effective than PVP-I both in vitro and in vivo. Therefore, there may be a need to re-evaluate this advice. In summary, we characterise the lipid membrane of SARS-CoV2, as being primarily comprised of PC, PE and PI, with a high proportion of external aPL, and show that the FA molecular species present may vary depending on host cell. Importantly, an inability to maintain asymmetry in the lipid envelope results in live virus being highly pro-coagulant. We also show that surfactant mouthwash that targets the lipid membrane may be a useful component of infection prevention and control strategies for respiratory enveloped viruses (e.g. influenza, SARS, MERS, in addition to SARS-CoV2), during a pandemic. They have the potential to lessen the risk of transmission from asymptomatic carriers to healthcare professionals performing oropharynx investigations, as well as transmission within the wider population, in a similar manner as to how they are being tested against pathogenic oral bacteria The membrane was stained with mouse anti-SARS-CoV2 Spike antibody and exposed for 30 sec. Bands corresponding to S1/S2 (~200kDa), and cleaved S1 (~80kDa) domains are observed. Panel B. Immunostaining of actin. The gel was stripped and reprobed with rabbit anti-actin antibody, then exposed for 3 min. Note that in addition to actin (~40kDa), incomplete stripping of anti-Spike antibody was also observed. J o u r n a l P r e -p r o o f *Zero counts were replaced with a value of 4; the lower limit of detection of the assay being 5 pfu/mL Assembly of the Semliki Forest virus membrane glycoproteins in the membrane of the endoplasmic reticulum in vitro Quantitative analysis of the lipidomes of the influenza virus envelope and MDCK cell apical membrane C1q binds phosphatidylserine and likely acts as a multiligandbridging molecule in apoptotic cell recognition Identification of a Golgi complex-targeting signal in the cytoplasmic tail of the severe acute respiratory syndrome coronavirus envelope protein The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal Sorting of progeny coronavirus from condensed secretory proteins at the exit from the trans-Golgi network of AtT20 cells Site of addition of N-acetyl-galactosamine to the E1 glycoprotein of mouse hepatitis virus-A59 Lipids of the Golgi membrane Viral apoptotic mimicry Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer Altan-Bonnet, and N. Altan-Bonnet. 2015. Phosphatidylserine vesicles enable efficient en bloc transmission of enteroviruses A pathogenic picornavirus acquires an envelope by hijacking cellular membranes Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry Role of phosphatidylserine receptors in enveloped virus infection Phosphatidylserine receptors enhance SARS-CoV-2 infection Novel lysophosphoplipid receptors: their structure and function Sphingolipid metabolites in inflammatory disease Platelet activation and blood coagulation Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells Lysophospholipids and their G protein-coupled receptors in atherosclerosis Role of lysophosphatidylcholine (LPC) in atherosclerosis Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A 2020. Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine In vitro assessment of the virucidal activity of four mouthwashes containing Cetylpyridinium Chloride, ethanol, zinc and a mix of enzyme and proteins against a human coronavirus Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2 Lowering the transmission and spread of human coronavirus In vitro studies evaluating the efficacy of mouth rinses on Sars-Cov-2: A systematic review Acosta-Hoyos. 2022. Virucidal Activity of Different Mouthwashes Using a Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial Nasopharyngeal and oropharyngeal rinses with neutral electrolyzed water prevents COVID-19 in front-line health professionals: A randomized, open-label 2021. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification LipidFinder 2.0: advanced informatics pipeline for lipidomics discovery applications Identification and quantification of aminophospholipid molecular species on the surface of apoptotic and activated cells Activated Partial Thromboplastin Time [APTT]. in Practical-Haemostasis.com, A Practical Guide to Haemostasis 40 Efficacy of Listerine Antiseptic in reducing viral contamination of saliva LMSD: LIPID MAPS structure database Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation Mechanically ventilated patients shed high titre live SARS-CoV2 for extended periods from both the upper and lower respiratory tract Analysis of the interactions of a cationic surfactant (lauric arginate) with an anionic biopolymer (pectin): isothermal titration calorimetry, light scattering, and microelectrophoresis Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses in vitro and in vivo A Throat Lozenge with Fixed Combination of Cetylpyridinium Chloride and Benzydamine Hydrochloride Has Direct Virucidal Effect on SARS-CoV-2 SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis Phospholipid synthesis and transport in mammalian cells Functional rafts in cell membranes Cellular cholesterol trafficking and compartmentalization Effect of cholesterol on the structure of a phospholipid bilayer Dynamics of the hydrocarbon layer in liposomes of lecithin and sphingomyelin containing dicetylphosphate Does Cholesterol Play a Role in the Bacterial Selectivity of Antimicrobial Peptides? G. Altan-Bonnet, and N. Altan-Bonnet. 2020. beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway Tracheal epithelial cell fatty acid composition modulates prostaglandin E2 and cAMP production Phospholipid fatty acid composition of pulmonary airway epithelial cells: potential substrates for oxygenation Influenza and cardiovascular disease: is there a causal relationship? Seasonal Influenza Infections and Cardiovascular Disease Mortality Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province Early postmortem mapping of SARS-CoV-2 RNA On the whereabouts of SARS-CoV-2 in the human body: A systematic review 2022. An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques Comparative study on the antiviral activity of selected monoterpenes derived from essential oils Analysis of Inactivation of SARS-CoV-2 by Specimen Transport Media, Nucleic Acid Extraction Reagents, Detergents, and Fixatives Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections Theory of Self-Assembly of Hydrocarbon Amphiphiles into Micelles and Bilayers Semiequilibrium dialysis study of the solubilization of benzoate anion by aqueous hexadecylpyridinium chloride Aggregation and adsorption behavior of cetylpyridinium chloride in aqueous sodium salicylate and sodium benzoate solutions Aggregation and reactivity in aqueous solutions of cationic surfactants and aromatic anions across concentration scales Mouthwash use in general population: results from adult dental health survey in grampian, Scotland Cytotoxicity and Antimicrobial Activity of Oral Rinses In Vitro Over-thecounter mouthwash use and risk of pre-diabetes/diabetes Efficacy of two mouthwashes with cetylpyridinium chloride: a controlled randomized clinical trial Association between periodontitis and severity of COVID-19 infection: A case-control study Comorbidity of periodontal disease: two sides of the same coin? An introduction for the clinician Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva Chlorhexidine mouthwash reduces the salivary viral load of SARS-CoV-2: A randomized clinical trial Effective in-vitro inactivation of SARS-CoV-2 by commercially available mouthwashes Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: a randomised controlled trial and an in vitro study Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group New thinking on gonorrhoea control in MSM: are antiseptic mouthwashes the answer? Antiseptic mouthwashes against sexually transmitted infections Writing -Original Draft, Visualisation, Supervision, Project Administration, Funding Acquisition (9) . Approximate phospholipid content is given as % total lipid phosphorus, data is averaged from several sources in both studies, as described.